SCHEMBL8918290

SCHEMBL8918290

OC(c1ccc2ncccc2c1)c1cccs1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.52
EGFR P00533 1/20 0.49
TOP2A P11388 1/20 0.49
TOP2B Q02880 1/20 0.49
MAPT P10636 4/20 0.48
HSD17B10 Q99714 2/20 0.48
MET P08581 2/20 0.44
NPC1 O15118 2/20 0.44
POLB P06746 2/20 0.44
RAB9A P51151 1/20 0.44
CHEK2 O96017 1/20 0.43
NR3C1 P04150 1/20 0.42
ALDH1A1 P00352 3/20 0.41
HTT P42858 3/20 0.41
ATM Q13315 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023643 0.83 NPC1 (0.57) TSHRMAPTHSD17B10METNPC1
SCHEMBL8917474 0.77 MET (0.54) TSHRMAPTHSD17B10METNPC1
SCHEMBL21709860 0.76 NPC1 (0.57) TSHRMAPTHSD17B10METNPC1
SCHEMBL188108 0.73 UGT2B7 (0.56) TSHRMAPTHSD17B10METNPC1
SCHEMBL4065050 0.73 NPC1 (0.53) TSHRMAPTHSD17B10METNPC1
SCHEMBL30745165 0.73 UGT2B7 (0.56) TSHRMAPTHSD17B10METNPC1
SCHEMBL13363674 0.72 ALDH1A1 (0.53) TSHRMAPTHSD17B10METNPC1
SCHEMBL15004363 0.71 TSHR (0.69) TSHREGFRTOP2ATOP2BMAPT
SCHEMBL9999689 0.71 MAPT (0.51) TSHRMAPTHSD17B10METNPC1
SCHEMBL27594316 0.71 NPC1 (0.46) TSHRMAPTHSD17B10METNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5612354-A CONTROLLING CELL GROWTH AND DIFFERENTIATION, RETINOIC ACID METABOLISM JANSSEN PHARMACEUTICA N.V. (BE) 1997-03-18 US disclosed
CN-1033752-C (1H-azol-1-ylmethyl) substituted quinoline or quinolinone derivatives JANSSEN PHARMACEUTICA NV (SE) 1997-01-08 CN disclosed
US-5441954-A Treatment of disorders characterized by increased proliferation and/or abnormal differentiation of cells JANSSEN PHARMACEUTICA N. V. (BE) 1995-08-15 US disclosed
CN-1106004-A A process for preparing (1H-azol-1-ylmethyl) substituted quinazoline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-08-02 CN disclosed
CN-1106005-A A process for preparing (1H-azol-1-ylmethyl) substituted quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-08-02 CN disclosed
EP-0371564-B1 (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-07-12 EP disclosed
US-5268380-A Therapy for keratinization in mammals JANSSEN PHARMACEUTICA N.V. (BE) 1993-12-07 US disclosed
US-5185346-A Antiandrogenic agents; suppress elimination of retinoids; anticarcinogenic agents HANSSEN PHARMACEUTICA (BE) 1993-02-09 US disclosed
CN-1042912-A (1H-oxazol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1990-06-13 CN disclosed
EP-0371564-A2 (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1990-06-06 EP disclosed